RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease
[EN] Aggregation of mutant huntingtin, because of an expanded polyglutamine track, underlies the cause of neurodegeneration in Huntington disease (HD). However, it remains unclear how some alterations at the cellular level lead to specific structural changes in HD brains. In this context, the neuroprotective effect of the activation of AMP-activated protein kinase (AMPK) appears to be a determinant factor in several neurodegenerative diseases, including HD. In the present work, we describe a series of indole-derived compounds able to activate AMPK at the cellular level. By using animal models of HD (both worms and mice), we demonstrate the in vivo efficacy of one of these compounds (IND1316), confirming that it can reduce the neuropathological symptoms of this disease. Taken together, in vivo results and in silico studies of druggability, allow us to suggest that IND1316 could be considered as a promising new lead compound for the treatment of HD and other central nervous system diseases in which the activation of AMPK results in neuroprotection., We thank the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440), for providing worm strains. RPVM is a Miguel Servet type II researcher (CPII16/00004) funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain). Grants from the ISCIII (PI17/00011 and PI20/00114), the Spanish Ministerio de Ciencia Innovacion y Universidades (RTI2018-095544-B-I00) and the Fundacio Marato de TV3 (Ref.: 559) were used to perform this work . All grants from ISCIII are co-financed by the European Development Regional Fund "A way to achieve Europe" (ERDF). Funds from the Fundacion Ramon Areces were also used (CIVP19S8119). J.B.Y . holds a grant by the Generalitat Valenciana and the European Social Fund (ACIF/2019/249). R.V.M. received an Ayuda Miguel Gil grant to RPVM (VII Convocatoria Ayudas a la Investigacion MHER, 2019, cofinanced by Colegio Oficial de Farmaceuticos de Sevilla and Fundacion Cajasol). R.V.M. has also received funds from the Asociacion Valenciana de Enfermedad de Huntington (AVAEH) . This work was also supported by an intramural ACCI2016 grant from the CIBERER-ISCiii to A.C., P.S., and R.V.M.
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-095544-B-I00
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20/00114
,
Ministerio de Economía y Competitividad CPII16/00004
,
Generalitat Valenciana ACIF/2019/249
,
Instituto de Salud Carlos III PI17/00011
,
National Institutes of Health P40 OD010440
,
EEUU ACCI 2016
,
Centro de Investigación Biomédica en Red de Enfermedades Raras CIVP19S8119